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A variant of Chlamydia trachomatis that had escaped 
detection by commonly used systems was discovered in 
Sweden in 2006. In a nationwide study, we found that it is 
now prevalent across Sweden, irrespective of the detec-
tion system used. Genetic analysis by multilocus sequence 
typing identifi ed a predominant variant, suggesting recent 
emergence. 
In 2006 a new variant of Chlamydia trachomatis (nvCT) was discovered in Sweden (1). Because of a 377-bp de-
letion in the target sequence for amplifi cation, the variant 
had escaped detection by 2 widely used nucleic acid ampli-
fi cation tests, Abbott m2000 (Abbott Laboratories, Abbott 
Park, IL, USA) and Cobas Amplicor/TaqMan48 (Roche 
Diagnostics, Basel, Switzerland) (1,2). The other test com-
monly used in Sweden, ProbeTec ET (Becton Dickinson 
[BD], Franklin Lakes, NJ, USA), detects the new variant 
because it uses a different DNA target sequence in the 
cryptic plasmid (3). The nvCT has now been reported from 
several of Sweden’s 21 counties (Figure 1). The aim of this 
study was to provide a national overview of the character-
istics and extent of the new chlamydia variant through ex-
amination of surveillance trends, microbiologic laboratory 
data, and genetic analysis of new variant strains. 
The Study
We examined national surveillance data reported 
to the Swedish Institute for Infectious Disease Control 
(Smittskyddsinstitutet) about chlamydia cases detected and 
the number of chlamydia tests performed. Trend analysis 
from 2004 to 2006 included only data for the fi rst 6 months 
of each year to avoid any infl uence of changes in detec-
tion systems; some counties introduced different detec-
tion systems in late 2006 in response to the emergence of 
nvCT. The statistical methods are described in the online 
Technical Appendix (available from http://www.cdc.gov/
EID/content/14/9/1462-Techapp.pdf). The total number of 
chlamydia cases detected in Sweden in the fi rst 6 months 
of 2006 was lower than that in 2005, and the proportion 
of tests that were positive also fell (Table 1). In 2004, the 
proportion of positive chlamydia tests was similar whether 
laboratories used Abbott/Roche or BD test systems. From 
2004 to 2005, there was a relative reduction of 3.4% (95% 
confi dence interval [CI] 5.8–1.0) in chlamydia positivity in 
laboratories using the Abbott or Roche methods (p = 0.006) 
but no change in the proportion of positive samples in lab-
oratories using the BD test system (–0.4%, 95% CI –4.2 
to +3.5). During the fi rst 6 months of 2005 and 2006, the 
positivity rates of samples tested by Abbott or Roche sys-
tems fell further; samples tested that used the BD system 
remained stable. The estimated difference in proportions 
of chlamydia-positive samples in counties that used Abbott 
or Roche tests compared with counties that used the BD 
method was –9.5 % (95% CI –14.1 to –4.7, p = 0.0005), 
after baseline differences and county differences in testing 
were controlled for. 
We conducted microbiologic analyses on consecutive 
samples that were collected from 12 counties in late 2006 
and early 2007. Cases of nvCT were identifi ed by testing 
specimens with additional methods using alternative se-
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Figure 1. Map of Sweden showing proportions of the new variant 
of Chlamydia trachomatis in different counties. Light gray shading 
indicates counties that used Abbott or Roche test systems before 
the discovery of the new variant; dark gray shading indicates 
counties that used the Becton Dickinson (BD) system. The 1 county 
that used both Roche and BD assays is indicated with stripes. n, 
number of positive chlamydia cases analyzed. The period in which 
samples were collected is given for each county.
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quence targets (online Technical Appendix). The propor-
tion of nvCT ranged from 20% to 64% in the 8 counties that 
used Abbott or Roche detection systems, compared with 
7% to 19%, respectively, for counties that used BD tests 
(Figure 1). Additional data about gender, age, and clini-
cal setting of diagnoses were available for 600 chlamyd-
ia-positive patients in the 4 counties using the BD system 
(Table 2). The proportion of nvCT cases varied between 
clinics (p = 0.020) and was higher at youth and venereal 
disease clinics than at antenatal and gynecology clinics. 
This variance might be because persons seeking treatment 
in these settings have higher levels of risk taking and more 
frequent changes in partners (4). There was no evidence of 
differences in the proportion of cases by gender (p = 0.103) 
or age (p = 0.558) because of nvCT. 
Genetic characterization with a new high-resolution 
genotyping system (5) was performed on 48 specimens of 
nvCT from 2 counties that used the BD test system (n = 
21); 2 counties that used Roche and Abbott systems (n = 
18); and 9 specimens from Norway, Ireland, and France 
(online Technical Appendix). The nvCT showed a new ge-
netic variant in the chromosomal target region hctB com-
pared with previous fi ndings in wild-type strains and thus 
constitutes a separate clone with the designation 21 (hctB), 
19 (CT058), 1 (CT144), 2 (CT172), and 1 (pbpB) in our 
system. All 48 specimens tested were of genotype E, and 
46 were identical in the ompA gene to the reference strain E/
Bour. The divergent specimens were from 2 persons known 
to be sexual partners and differed in a single nucleotide po-
sition. In the other 5 target genes, altogether comprising 
some 5,500 bp, all 48 specimens were identical. 
Conclusions
Our study was a national systematic overview includ-
ing surveillance, demographic, microbiologic, and genetic 
data about the emergence and spread of a mutant strain of C. 
trachomatis in Sweden. A fall in the proportion of positive 
chlamydia test results in counties using Abbott or Roche test 
systems began in 2005 and continued in 2006, whereas posi-
tivity rates in counties using BD tests did not change. The 
mutant strain has now spread throughout Sweden. Notably, 
the new variant has scarcely been found outside Sweden (6), 
indicating that we need to improve our understanding of the 
sexual networks through which chlamydiae spread (7).
Our analysis suggests that widespread transmission of 
nvCT is recent, even if the mutation itself occurred some 
time ago, because 46 of 48 specimens from different places 
had identical sequences when we used a highly discrimina-
tory multilocus sequence typing system (5). This hypoth-
esis is supported by the lack of diversifi cation in the mutant 
strains compared with the high degree of sequence varia-
tion in other sample collections that we have analyzed (5; 
and unpub. data). We expect new nucleotide substitutions 
to occur over time. 
The area in Sweden in which nvCT originated is not 
known, but the consistently high proportion of nvCT found 
in the county of Dalarna suggests that the mutant might 
have been present in this region for longer than in other 
counties studied. nvCT comprised 64% of chlamydia-posi-
tive specimens over the study period in Dalarna as a whole, 
and up to 78% in some localities (7); elsewhere in Sweden 
(8–10) and worldwide (11,12), genotype E strains of dif-
ferent subvariants comprise ≈40% of chlamydia-positive 
speciments in heterosexual populations. These data might 
indicate that the high proportion of nvCT is not only a re-
sult of accumulation of chlamydia cases when diagnostics 
failed and treatment and contact tracing were inadequate. 
Further studies will be needed to determine whether nvCT 
also has a selective advantage that might outcompete the 
wild-type bacterium over time. 
The emergence of this mutant strain of a sexually trans-
mitted pathogen has implications for public health practice. 
A recent study estimates that some 8,000 chlamydia cases 
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Table 1. Numbers of chlamydia tests, positive results, and change in positivity rates, Sweden, 2004–2006  
No. positive results/total no. tests (%) in first 6 mo 
Diagnostic test* No. counties 2004 2005 2006
Abbott/Roche 14 11,721/150,080 (7.8) 11,111/147,311 (7.5) 10,236/152,960 (6.7) 
Becton Dickinson 8 4,262/54,260 (7.9) 5,220/66,728 (7.8) 3,363/43,189 (7.8) 
All tests 21 15,983/204,340 (7.8) 16,331/214,039 (7.6) 13,599/196,149 (6.9) 
*One county used both Roche and Becton Dickinson tests. 
Table 2. Distribution of cases of nvCT by gender, age, and clinic 
category in 4 selected counties that used the Becton Dickinson 
system* 
Factor % nvCT (n/N) p value† 
Gender   
 Male 16 (45/273) 0.103 
 Female 12 (39/327)  
Age, y   
 15–19 14 (23/162) 0.558 
 20–24 16 (44/279)  
 25–29 11 (11/98)  
 >30 10 (6/59)  
Clinic   
 Venereal disease 15 (19/129) 0.020 
 Youth clinics 19 (39/210)  
 Gynecology 9 (13/150)  
 Antenatal/general practice 8 (6/77)  
 Others 21 (7/34)  
*nvCT, new variant of Chlamydia trachomatis; n, number of nvCT cases 
detected; N, total number of C. trachomatis cases detected. 
†Determined by ?2 test. 
escaped detection in 2006 (7). This would have resulted 
in an ≈20% increase in reported chlamydia cases. Actual 
national fi gures for 2007 confi rm such an increase, and 
the number of reported chlamydia cases has reached an 
all-time high in Sweden (Figure 2). Chlamydia infections, 
caused not only by nvCT, continue to rise (13,14), but the 
areas most heavily affected by the spread of nvCT have 
been in much the same situation as before chlamydia was 
fi rst recognized as a pathogen. Failure to detect the nvCT 
over time have resulted in episodes of complicated infec-
tion all over the country, leading to ectopic pregnancies and 
infertility. Research is now needed to determine whether se-
quelae associated with chlamydia occur disproportionately 
in counties where test systems fail to diagnose the nvCT. 
The ability of this new variant to escape detection for so 
long shows that developers of future diagnostic tests need 
to take into account the structure and function of genomes 
when selecting appropriate target nucleic acid sequences in 
microorganisms. Currently, there are unique opportunities 
for research that could lead to insights into the immunobi-
ology, transmission, and consequences of C. trachomatis.  
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Figure 2. Chlamydia trachomatis reports, Sweden, 1991–2007. The 
number of persons examined and cases detected in 2007, when 
diagnostic tests for chlamydia had been changed, is in line with the 
increasing trend from 2004 and before. The fi gures for 2005 and 
2006 refl ect the failure to detect cases of the new chlamydia variant 
in some counties.
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